Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Treatment of vaso-occlusive crises (VOC) or events in sickle cell disease (SCD) remains limited to symptom relief with opioids. Animal models support the effectiveness of the pan-selectin inhibitor GMI-1070 in reducing selectin-mediated cell adhesion and abrogating VOC. We studied GMI-1070 in a pros...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Telen, Marilyn J., Wun, Ted, McCavit, Timothy L., De Castro, Laura M., Krishnamurti, Lakshmanan, Lanzkron, Sophie, Hsu, Lewis L., Smith, Wally R., Rhee, Seungshin, Magnani, John L., Thackray, Helen
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2015
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4408290/
https://ncbi.nlm.nih.gov/pubmed/25733584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-583351
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires